## **GRIN2B-related** neurodevelopmental disorder

https://pubmed.ncbi.nlm.nih.gov/29851452/

Clinical characteristics:
GRIN2B
-related neurodevelopmental disorder is characterized by mild to profound developmental delay /
intellectual disability (DD/ID) in all affected individuals. Muscle tone abnormalities (spasticity and/or
hypotonia, occasionally associated with feeding difficulties), as well as epilepsy and autism
spectrum disorder (ASD) / behavioral issues, are common. Other infantile- or childhood-onset
findings include microcephaly; dystonic, dyskinetic, or choreiform movement disorder; and/or cortical
visual impairment. Brain MRI reveals a malformation of cortical development in a minority of affected
individuals. To date, fewer than 100 individuals with
GRIN2B
-related neurodevelopmental disorder have been reported.
Diagnosis/testing:

GRIN2B
-related neurodevelopmental disorder is established in a proband by identification of either a
heterozygous pathogenic variant or exon or whole-gene deletion of
GRIN2B
on molecular genetic testing.
Management:
Treatment of manifestations:
DD/ID, muscle tone abnormalities (spasticity, hypotonia, and feeding difficulties), epilepsy,
ASD/behavioral issues, movement disorders, and/or cortical visual impairment are treated as per
standard practice.
Surveillance:
Of clinical manifestations as clinically indicated.

The diagnosis of a

<u> </u>		
Genetic	counselina:	

## **GRIN2B**

-related neurodevelopmental disorder is inherited in an autosomal dominant manner. All probands reported to date with a

## **GRIN2B**

-related neurodevelopmental disorder whose parents have undergone molecular genetic testing have the disorder as a result of a

de novo GRIN2B

pathogenic variant or deletion. If the proband represents a simplex case (i.e., the only affected family member) and the

## GRIN2B

pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is estimated to be 1% because of the theoretic possibility of parental mosaicism. Given this risk, prenatal testing and preimplantation genetic testing may be considered.